Reports Q2 revenue $1.28B, consensus $1.27B. “Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS ...

ResMed has beaten earnings forecasts in the second quarter due to higher sales of its sleep device products and masks despite fears that the take-up of weight-loss drugs would reduce demand as ...

ResMed Inc.’s RMD adjusted earnings per share (EPS) in the second quarter of fiscal 2025 were $2.43, up 29.2% year over year.

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

Sleep device giant ResMed expects to benefit from Donald Trump’s trade tariffs and tax cuts if competitors making rival products in China and Mexico are slapped with additional duties when they ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Jan 30 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common ...

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...

ResMed (NYSE:RMD – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, ...